Skip to content

Bluebird bio’s Lentiglobin nabs PRIME status in Europe

September 23, 2020

Bluebird bio’s (NASDAQ:BLUE) LentiGlobin, an investigational gene therapy (bb1111) for the treatment of sickle cell disease (SCD), was granted eligibility to the Priority Medicines (PRIME) program by the EMA.

PRIME, akin to Breakthrough Therapy status in the U.S., provides for more intensive guidance on development and accelerated review of the market application.

SCD is a progressive and debilitating genetic disease caused by a mutation in the β-globin gene that leads to the production of abnormal sickle hemoglobin (HbS), resulting in chronic hemolytic anemia and vasculopathy.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: